Covington Capital Management’s INmune Bio INMB Stock Holding History

Covington Capital Management’s Portfolio INMB Stock Details INMB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$6K	Hold	1,000	–	–	﹤0.01%	895
2022 Q2	$9K	Hold	1,000	–	–	﹤0.01%	826
2022 Q1	$8K	Hold	1,000	–	–	﹤0.01%	865
2021 Q4	$10K	Hold	1,000	–	–	﹤0.01%	784
2021 Q3	$19K	Hold	1,000	–	–	﹤0.01%	708
2021 Q2	$18K	Hold	1,000	–	–	﹤0.01%	685
2021 Q1	$12K	Hold	1,000	–	–	﹤0.01%	670
2020 Q4	$17K	Hold	1,000	–	–	﹤0.01%	606
2020 Q3	$10K	Hold	1,000	–	–	﹤0.01%	637
2020 Q2	$5K	Hold	1,000	–	–	﹤0.01%	693
2020 Q1	$3K	Hold	1,000	–	–	﹤0.01%	712
2019 Q4	$6K	Hold	1,000	–	–	﹤0.01%	745
2019 Q3	$6K	Buy	+1,000	New	+$7.4K	﹤0.01%	717

Other funds holding INMB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $40.4B AUM 21.2% 1-Year Est. Return

ACM

ACT Capital Management Wayne, Pennsylvania $153M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Covington Capital Management's INMB Position: Q3 2022 in Review

Covington Capital Management held its INmune Bio (INMB) position steady in Q3 2022 at 1,000 shares worth $6K. The position accounts for ﹤0.01% of the portfolio, ranked #895.

Covington Capital Management first reported a position in INMB in Q3 2019 and has held it in 13 quarters since. The position peaked at $19K in Q3 2021. 33 funds tracked by Wall St. Rank hold INMB as of Q3 2022.

Covington Capital Management held 1,000 shares of INmune Bio worth $6K as of Q3 2022.
Covington Capital Management left its INmune Bio share count unchanged in Q3 2022.
INmune Bio made up ﹤0.01% of Covington Capital Management's portfolio in Q3 2022, its #895 holding.
Covington Capital Management first reported a position in INmune Bio in Q3 2019 and has held it in 13 quarters since.
Covington Capital Management's INmune Bio position peaked at $19K in Q3 2021.
33 funds tracked by Wall St. Rank held INmune Bio as of Q3 2022.

Based on Covington Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.